000142134 001__ 142134
000142134 005__ 20240229105145.0
000142134 0247_ $$2doi$$a10.1038/s41418-018-0080-0
000142134 0247_ $$2pmid$$apmid:29515255
000142134 0247_ $$2pmc$$apmc:PMC6261943
000142134 0247_ $$2ISSN$$a1350-9047
000142134 0247_ $$2ISSN$$a1476-5403
000142134 0247_ $$2altmetric$$aaltmetric:34312097
000142134 037__ $$aDKFZ-2018-02364
000142134 041__ $$aeng
000142134 082__ $$a610
000142134 1001_ $$0P:(DE-He78)cd7eb75e4b89ac0b520b75c4f63b272f$$aShen, Jing$$b0$$eFirst author$$udkfz
000142134 245__ $$aA kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
000142134 260__ $$aLondon$$bMacmillan$$c2018
000142134 3367_ $$2DRIVER$$aarticle
000142134 3367_ $$2DataCite$$aOutput Types/Journal article
000142134 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550747062_13723
000142134 3367_ $$2BibTeX$$aARTICLE
000142134 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142134 3367_ $$00$$2EndNote$$aJournal Article
000142134 520__ $$aThe prognosis of advanced stage neuroblastoma patients remains poor and, despite intensive therapy, the 5-year survival rate remains less than 50%. We previously identified histone deacetylase (HDAC) 8 as an indicator of poor clinical outcome and a selective drug target for differentiation therapy in vitro and in vivo. Here, we performed kinome-wide RNAi screening to identify genes that are synthetically lethal with HDAC8 inhibitors. These experiments identified the neuroblastoma predisposition gene ALK as a candidate gene. Accordingly, the combination of the ALK/MET inhibitor crizotinib and selective HDAC8 inhibitors (3-6 µM PCI-34051 or 10 µM 20a) efficiently killed neuroblastoma cell lines carrying wildtype ALK (SK-N-BE(2)-C, IMR5/75), amplified ALK (NB-1), and those carrying the activating ALK F1174L mutation (Kelly), and, in cells carrying the activating R1275Q mutation (LAN-5), combination treatment decreased viable cell count. The effective dose of crizotinib in neuroblastoma cell lines ranged from 0.05 µM (ALK-amplified) to 0.8 µM (wildtype ALK). The combinatorial inhibition of ALK and HDAC8 also decreased tumor growth in an in vivo zebrafish xenograft model. Bioinformatic analyses revealed that the mRNA expression level of HDAC8 was significantly correlated with that of ALK in two independent patient cohorts, the Academic Medical Center cohort (n = 88) and the German Neuroblastoma Trial cohort (n = 649), and co-expression of both target genes identified patients with very poor outcome. Mechanistically, HDAC8 and ALK converge at the level of receptor tyrosine kinase (RTK) signaling and their downstream survival pathways, such as ERK signaling. Combination treatment of HDAC8 inhibitor with crizotinib efficiently blocked the activation of growth receptor survival signaling and shifted the cell cycle arrest and differentiation phenotype toward effective cell death of neuroblastoma cell lines, including sensitization of resistant models, but not of normal cells. These findings reveal combined targeting of ALK and HDAC8 as a novel strategy for the treatment of neuroblastoma.
000142134 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142134 588__ $$aDataset connected to CrossRef, PubMed,
000142134 7001_ $$0P:(DE-He78)f08873535c440e3ce033c84d5786f70f$$aNajafi, Sara$$b1$$udkfz
000142134 7001_ $$0P:(DE-He78)382c3025ef63551628ccc5bc5e702034$$aStäble, Sina$$b2$$udkfz
000142134 7001_ $$0P:(DE-HGF)0$$aFabian, Johannes$$b3
000142134 7001_ $$0P:(DE-He78)700a3a9eaae170adaad6cfbd3d696f93$$aKoeneke, Emily$$b4$$udkfz
000142134 7001_ $$0P:(DE-He78)556dfbcf5489cf998946e2b316deca4d$$aKolbinger, Fiona$$b5$$udkfz
000142134 7001_ $$0P:(DE-He78)cacc65ce8c4dddde923bc91eb6631dad$$aWrobel, Jagoda$$b6$$udkfz
000142134 7001_ $$aMeder, Benjamin$$b7
000142134 7001_ $$aDistel, Martin$$b8
000142134 7001_ $$aHeimburg, Tino$$b9
000142134 7001_ $$aSippl, Wolfgang$$b10
000142134 7001_ $$aJung, Manfred$$b11
000142134 7001_ $$aPeterziel, Heike$$b12
000142134 7001_ $$0P:(DE-He78)17cf3454cef0265578352ab023676b70$$aKranz, Dominique$$b13$$udkfz
000142134 7001_ $$0P:(DE-He78)3c0da8e3caa2aa50cad85152aa0465ad$$aBoutros, Michael$$b14$$udkfz
000142134 7001_ $$0P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aWestermann, Frank$$b15$$udkfz
000142134 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b16$$udkfz
000142134 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b17$$eLast author$$udkfz
000142134 773__ $$0PERI:(DE-600)1496681-5$$a10.1038/s41418-018-0080-0$$gVol. 25, no. 12, p. 2053 - 2070$$n12$$p2053 - 2070$$tCell death and differentiation$$v25$$x1476-5403$$y2018
000142134 909CO $$ooai:inrepo02.dkfz.de:142134$$pVDB
000142134 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL DEATH DIFFER : 2017
000142134 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142134 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142134 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142134 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142134 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142134 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142134 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142134 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142134 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142134 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142134 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142134 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142134 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL DEATH DIFFER : 2017
000142134 9141_ $$y2018
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cd7eb75e4b89ac0b520b75c4f63b272f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f08873535c440e3ce033c84d5786f70f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)382c3025ef63551628ccc5bc5e702034$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)700a3a9eaae170adaad6cfbd3d696f93$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)556dfbcf5489cf998946e2b316deca4d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cacc65ce8c4dddde923bc91eb6631dad$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)17cf3454cef0265578352ab023676b70$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3c0da8e3caa2aa50cad85152aa0465ad$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000142134 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000142134 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142134 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x0
000142134 9201_ $$0I:(DE-He78)B110-20160331$$kB110$$lSignalwege und Funktionelle Genomik$$x1
000142134 9201_ $$0I:(DE-He78)B087-20160331$$kB087$$lNeuroblastom Genomik$$x2
000142134 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x3
000142134 9201_ $$0I:(DE-He78)L601-20160331$$kL601$$lDKTK Freiburg$$x4
000142134 980__ $$ajournal
000142134 980__ $$aVDB
000142134 980__ $$aI:(DE-He78)L101-20160331
000142134 980__ $$aI:(DE-He78)B110-20160331
000142134 980__ $$aI:(DE-He78)B087-20160331
000142134 980__ $$aI:(DE-He78)G340-20160331
000142134 980__ $$aI:(DE-He78)L601-20160331
000142134 980__ $$aUNRESTRICTED